Publications by authors named "Julia Wosniok"
Article Synopsis
- There’s a significant need for new treatments for relapsed diffuse large B-cell lymphoma, and the mTOR inhibitor temsirolimus showed potential when combined with a standard salvage regimen.
- A study was conducted using the STORM regimen, which included rituximab and DHAP, with temsirolimus being added at a managed dose depending on patient reactions.
- The results showed a 66% overall response rate and good tolerability, with 2-year progression-free survival at 53% and overall survival at 59%, indicating that this combination therapy could be a promising option for patients.
Airway inflammation and chronic lung infections in cystic fibrosis (CF) patients are mostly caused by bacteria, e.g. Pseudomonas aeruginosa (PA).
View Article and Find Full Text PDFBackground: Oral glucose tolerance (OGT) deteriorates progressively in cystic fibrosis (CF). Clinical registries provide a unique basis to study real-world data.
Patients & Methods: OGT tests (OGTTs) documented in the German CF-registry in 2016 were classified according WHO, modified by ADA: normal glucose tolerance (NGT), indeterminate glycaemia (INDET), impaired fasting glucose (IFG), impaired glucose tolerance (IGT), IFG+IGT, diabetes mellitus (DM).